MedTrace Logo

Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma

NCT02615106 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-06-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Radiotherapy plus Endostar(Recombinant Human Endostatin) in patients with Pediatric Neuroblastoma.

Conditions

Interventions

DRUG

Endostar

7.5 mg/m2/day, day 1-14

RADIATION

21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor

21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor

Sponsors & Collaborators

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • mawei jiang, MD · The Department of Radiation Oncology, Xin Hua Hospital affiliated to Shanghai Jiaotong University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-11-30
Completion
2018-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02615106 on ClinicalTrials.gov